GB1433774A — Heterocyclic compounds apparatus for conveying articles
Assigned to Allen and Hanburys Ltd · Expires 1976-04-28 · 50y expired
What this patent protects
1433774 Tetrazole-derived amides ALLEN & HANBURYS 6 Feb 1974 [26 Feb 1973] 9249/73 Heading C2C The invention comprises compounds of formula their 4-oxyquinoline tautomers (when R 4 =H) and pharmaceutically acceptable salts and esters thereof, in which : R 1 and R 2 which ma…
USPTO Abstract
1433774 Tetrazole-derived amides ALLEN & HANBURYS 6 Feb 1974 [26 Feb 1973] 9249/73 Heading C2C The invention comprises compounds of formula their 4-oxyquinoline tautomers (when R 4 =H) and pharmaceutically acceptable salts and esters thereof, in which : R 1 and R 2 which may be the same or different represent a hydrogen atom, a halogen atom, or an alkyl, trifluoromethyl or nitro group, or a group OR 3 in which R 3 represents a hydrogen atom, or an alkenyl or alkyl group, which alkyl group may be substituted by alkoxy, aryl, amino, alkylamino, dialkylamino, hydroxy or acyloxy groups; or a group NR 6 R 7 in which R 6 and R 7 which may be the same or different represent a hydrogen atom or an alkyl group, which alkyl group may be substituted with a hydroxy or acyloxy group, or in which R 6 and R 7 together with the nitrogen atom form a 5- or 6-membered ring which may contain additional hetero atoms; R 4 represents a hydrogen atom, an alkenyl or alkyl group, which alkyl group may be substituted with hydroxy, acyloxy, alkoxy, aryl, amino, alkylamino, dialkylamino or alkylaralkylamino groups; and R 5 represents a hydrogen atom or an alkyl group. In examples, these compounds are prepared by reacting the corresponding quinolonecarboxylic acid (A) (or a functional derivative thereof such as the acid chloride or the mixed anhydride with EtOCO 2 H) with 5-aminotetrazole and by the interconversion of functional groups in compounds thus prepared; the acids (A) are made by hydrolysing the corresponding esters. Therapeutic compositions for treating conditions primarily caused by antigen/reaginic antibody combination comprise compounds of the above formula, and may be administered orally or by inhalation.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.